- Created on the 22 March, 2017.
C-reactive protein (CRP) is produced exclusively in the liver and it is interleukin-6 (IL-6) which is the chief mediator for the synthesis of CRP by hepatocytes. It has a total approx. molecular mass of 120.000 Daltons and is made up of a symmetrical pentamer structure. Human CRP is essentially a kind of non-immunoglobulin serum substance which is also a heat labile beta-globulin. It is found to be present in the active stages of many inflammatory disorders such as rheumatoid arthritis, psoriatric arthropathy, Crohn’s disease, systemic lupus erythematosus, Reiter’s syndrome, polyarteritis, ankylosing spondylitis and ulcerative colitis.
The CRP-level can increases dramatically after microbial infections and this property has been particularly helpful for the diagnosis and monitoring a large number of bacterial septicemia in neonates and in many other immune-compromised patients. The concentrations of CRP begin to rise within 6 hours of an acute inflammatory challenge. Also, many injuries that are responsible for causing necrosis and tissue breakdown are also found to elevate serum CRP levels, examples of these are observed in major surgery, myocardial infarction and thermal burns. A number of widespread malignant diseases including Hodgkin’s disease, lymphosarcoma, non-Hodgkin’s lymphoma and many carcinomas (lung, pancreas, stomach, breast, colon and prostate) can also give rise to high levels of CRP which result from tissue damage that is caused by invading tumour cells. CRP has therefore been used as a good marker to monitor malignancy.
Human hsCRP ELISA kit is a method for analysing in vitro quantitative concentrations of high sensitive c-reactive protein (hsCRP) in human serum and plasma. This assay has a minimum detection limit of < 0.02 µg/ml.
The minimum detection sensitivity level of c-reactive protein (CRP) using this human hsCRP ELISA kit was 0.02 µg/ml. The dynamic assay range for this kit is 0.4 – 10.0 µg /ml.
- Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacing Clin Electrophysiol. (2009) 32 (5): 648-52. Crandall M.A., et al.
- High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening? Int Angiol. (2003) 22 (1): 15-23. Review. Sellmayer A., et al.
- Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J. (2004) 2 (4 Suppl 1): 4-9. Review. Ridker P.M.
- Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Clin Chem. (2009) 55 (2): 256-64. Review. Shen J. and Ordovas J.M.
- Full Name: High Sensitive C-Reactive Protein (hsCRP) ELISA Kit
- Reactivity: Human
- Sample Type: Plasma, Serum
- Sensitivity: < 0.02 µg/ml